Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM1YEPS)

Drug Name
Volanesorsen Drug Info
Indication
Disease Entry ICD 11 Status REF
Hypertriglyceridemia 5C80.1 Approved [1]
Hyperlipoproteinemia 5C80 Phase 3 [2]
Familial chylomicronemia syndrome 5C80 Phase 1 [3]
Cross-matching ID
PubChem CID
121494123
TTD Drug ID
DM1YEPS

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting ApoC-III messenger RNA (APOC3 mRNA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
ARO-APOC3 DMABKHH Familial chylomicronemia syndrome 5C80 Phase 3 [4]
Olezarsen DMNLSFN Familial chylomicronemia syndrome 5C80 Phase 3 [5]
ISIS-APOCIII DMX3FN4 Atherosclerosis BD40 Phase 1 [6]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
ApoC-III messenger RNA (APOC3 mRNA) TTXOZQ1 APOC3_HUMAN Inhibitor [1]

References

1 Metabolism and Disposition of Volanesorsen, a 2'- O-(2 methoxyethyl) Antisense Oligonucleotide, Across Species. Drug Metab Dispos. 2019 Oct;47(10):1164-1173.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8681).
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets. Curr Atheroscler Rep. 2021 Mar 10;23(5):20.
5 Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. Eur Heart J. 2022 Apr 6;43(14):1401-1412.
6 Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).